Strepsils Intensive, sugar-free orange tablets 24 pcs

Flurbiprofen is a derivative of propionic acid from the group of non-steroidal anti-inflammatory drugs (NSAIDs) and has significant analgesic, anti-inflammatory and antipyretic effect due to inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), with some selectivity for COX-1, resulting in reduced production of prostaglandins – mediators of pain, inflammation and hyperthermic response.

The drug has a local anesthetic and anti-inflammatory effect on the mucous membrane of the mouth and throat: it reduces swelling, difficulty in swallowing, pain and irritation in the throat.

The tablet dissolves completely in the mouth within 5-12 minutes. The soothing effect starts from the 2nd minute.

The significant reduction in the intensity of sore throat begins at 22 minutes with maximum effect after 70 minutes and lasts up to 4 hours.

Pharmacokinetics

The tablet dissolves completely in the mouth within 5-12 minutes. Absorption is high, flurbiprofen is quickly and almost completely absorbed, distributed throughout the body and largely bound to plasma proteins. Flurbiprofen is detected in blood after 5 min, maximum concentration of flurbiprofen in blood plasma (Cmax) is reached after 40-45 minutes after resorption.

Flurbiprofen can be absorbed in the oral cavity by passive diffusion. Absorption rate depends on the dosage form; maximum concentration of flurbiprofen is reached faster by resorption than by oral administration of an equivalent dose of flurbiprofen.

The elimination half-life (T1/2) is 3-6 hours. It is metabolized in liver by hydroxylation and excreted by kidneys and, to a lesser extent, with bile. Flurbiprofen is excreted with breast milk in small amounts (< 0.05 µg/ml). About 20-25 % of the oral dose of flurbiprofen is excreted unchanged.

Indications

Active ingredient

Composition

One snifter tablet contains

the active ingredient:

flurbiprofen 8.75 mg,

excipients:

consumption tablets [honey lemon]:

macrogol 300 5.47 mg,

potassium hydroxide 2.19 mg,

sucrose liquid 1407 mg,

levomenthol 2 mg,

dextrose 1069 mg,

honey 50.4 mg,

lemon flavoring (502904 A) 3.6 mg.

consumption tablets [orange]:

macrogol 300 5.47 mg,

potassium hydroxide 2.19 mg,

PHL-010300 orange flavoring 10 mg,

p> levomenthol 2 mg,

acetulfame potassium 3 mg,

isomalt 2033.29 mg,

maltitol liquid 509.31 mg.

How to take, the dosage

Read the instructions carefully before using the product.

For topical use. For short-term use only.

Adults and children over 12 years of age: Slowly swallow 1 tablet every 3 to 6 hours.

The maximum daily dose: 5 tablets over 24 hours.

The duration of therapy: not more than 3 days.

If symptoms persist or worsen when taking the drug for 3 days, you should stop treatment and see a doctor.

Interaction

Special Instructions

It is recommended that the drug be taken in as short a course as possible and in the lowest effective dose necessary to relieve symptoms.

Persons with diabetes should be aware that each honey lemon sippy tablet contains about 2.5 grams of sugar (0.21 CFU) (orange sippy tablets contain no sugar).

The orange sippy lozenges contain maltitol liquid and isomalt (the maximum daily dose of which is more than 2 g), so they may have a laxative effect.

In case of symptoms of gastropathy, close monitoring is indicated, including esophagogastroduodenoscopy, complete blood count (hemoglobin determination), fecal occult blood test.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

Ethanol intake is not recommended during treatment.

Patients with renal or hepatic impairment, as well as elderly patients and patients taking diuretics should consult a physician before using the drug, since there is a risk of impairment of renal function. In short-term use of the drug the risk is insignificant.

Patients with arterial hypertension, including a history of and/or chronic heart failure, should consult a physician before using the drug, as the drug may cause fluid retention, increased blood pressure, and edema.

Information for women planning pregnancy: The drug suppresses cyclooxygenase and prostaglandin synthesis and may affect ovulation, impairing female fertility (reversible after discontinuation of treatment).

In case of irritation in the oral cavity, skin rash, mucosal lesions and other manifestations of allergic reaction, the drug should be stopped and a physician should be consulted.

If there is a worsening of symptoms or if new symptoms develop, including evidence of bacterial infection, you should see a physician immediately so that the therapy can be revised.

Synopsis

Contraindications

With the conditions listed in this section, consult a physician before using the drug.

Concomitant use of other NSAIDs; history of a single episode of peptic ulcer disease or peptic ulcer bleeding; history of gastrointestinal diseases (ulcerative colitis, Crohn’s disease), gastritis, enteritis, colitis, the presence of Helicobacter pylori infection; bronchial asthma or allergic diseases in the acute stage or in the history – bronchospasm may develop; systemic lupus erythematosus or mixed connective tissue disease (Sharp’s syndrome) – increased risk of aseptic meningitis (with short-term use of flurbiprofen the risk is negligible); renal failure including dehydration (creatinine clearance less than 30-60 ml/min), nephrotic syndrome; liver failure, cirrhosis with portal hypertension, hyperbilirubinemia; arterial hypertension and/or heart failure, edema; concomitant use of drugs that may increase the risk of ulceration or bleeding, in particular oral glucocorticosteroids (including prednisolone), anticoagulants (including warfarin), antiaggregants (including acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) I-II trimester pregnancy, breastfeeding, old age, and alcohol use.

Side effects

The risk of side effects can be minimized by taking a short course of the drug at the lowest effective dose necessary to control symptoms.

The following adverse reactions have been reported with short-term use. Other adverse reactions may occur with chronic conditions and long-term use.

The incidence of adverse reactions was estimated based on the following criteria: very common (≥ 1/10), common (≥ 1/100 to < 1/10), infrequent (≥ 1/1000 to < 1/100), rare (≥ 1/10 000 to < 1/1000), very rare (< 1/10 000), frequency unknown (no data on frequency estimates).

Blood and lymphatic system disorders

Nervous system disorders

Immune system disorders

Heart disorders

Vascular disorders

Respiratory system, thoracic and mediastinal disorders

Gastrointestinal disorders

Skin and subcutaneous tissue disorders

Hepatic and biliary tract disorders

Mental disorders

Other

Overdose

Symptoms: nausea, vomiting, epigastric pain or, less frequently, diarrhea, tinnitus, headache and gastrointestinal bleeding. In more severe cases, manifestations of the central nervous system are observed: drowsiness, rarely – agitation, seizures, disorientation, coma.

In cases of severe poisoning metabolic acidosis and increased prothrombin time, acute renal failure, liver tissue damage, decreased blood pressure, respiratory depression and cyanosis may develop. In patients with bronchial asthma, exacerbation of this disease is possible.

The treatment: symptomatic, with mandatory provision of airway patency, ECG monitoring and basic vital signs until the patient’s condition normalizes. Oral administration of activated charcoal or gastric lavage within 1 hour after taking a potentially toxic dose of flurbiprofen is recommended.

Frequent or prolonged seizures should be controlled by intravenous administration of diazepam or lorazepam. If bronchial asthma worsens, the use of bronchodilators is recommended. There is no specific antidote to flurbiprofen.

Similarities